STUDY DESIGN
GRIPHON Is the Largest PAH Pivotal Trial With the Longest Endpoint Evaluation Period of Any Prostacyclin Pathway Therapy1-3
GRIPHON is the largest adult PAH pivotal trial, studied as monotherapy, dual therapy (ERA or PDE5i), and triple therapy (ERA + PDE5i)1,2
Multicenter, long-term, double-blind, placebo-controlled, parallel-group, event-driven, phase 3 trial1,3
1156 Patients
UPTRAVI
(selexipag): n=574
Placebo:
n=582
Mean age:
48 years
Female:
80%
1.4 Years
(median duration of exposure to UPTRAVI)
Longest endpoint evaluation period of any prostacyclin pathway therapy
0.9 YearsÂ
Median time from PAH diagnosis in patients taking UPTRAVI
New England Journal of Medicine Clinical Trial Publication for GRIPHON
This article includes information that has not been approved by the Food and Drug Administration for UPTRAVI. Please see full Prescribing Information available on this website. Authors[s] of this article have received remuneration from Actelion Pharmaceuticals US, Inc., or its affiliates.
6MWD=6-minute walk distance; ERA=endothelin receptor antagonist; FC=Functional Class; GRIPHON=Prostacyclin (PGI2) Receptor Agonist In Pulmonary Arterial HypertensiON; HIV=human immunodeficiency virus; HPAH=heritable PAH; IPAH=idiopathic PAH; PAH-CHD=PAH associated with congenital heart disease with repaired shunts; PAH-CTD=PAH associated with connective tissue disease; PDE5i=phosphodiesterase type-5 inhibitor; WHO=World Health Organization.
1. (selexipag) full Prescribing Information. Actelion Pharmaceuticals US, Inc. 2. Sitbon O, Gomberg-Maitland M, Granton J, et al. Clinical trial design and new therapies for pulmonary arterial hypertension. Eur Respir J. 2019;53(1):1801908. doi:10.1183/13993003.01908-2018 3. Data on file. Actelion Pharmaceuticals US, Inc. Length and Population Size of PAH Pivotal Trials Confirmation. June 2024. 4. Sitbon O, Channick R, Chin KM, et al. Selexipag for the treatment of pulmonary hypertension. N Engl J Med. 2015;373:2522-2533 and suppl. 5. Data on file. Actelion Pharmaceuticals US, Inc. GRIPHON Baseline Characteristics Study Report.
